No Data
Henan Jindan Lactic Acid Technology (300829.SZ): cumulative repurchase of 1.12% of shares
Gelonghui November 1st | Henan Jindan Lactic Acid Technology (300829.SZ) announced that, as of October 31, 2024, the company repurchased 2,079,180 shares of the company through a special securities account for stock repurchase through centralized bidding trading, accounting for 1.12% of the total share capital. The highest fill price was 15.50 yuan/share, the lowest fill price was 13.23 yuan/share, and the total fill amount was RMB 30,041,503.90 (excluding transaction taxes and fees).
Jindan Technology: Report for the third quarter of 2024
henan jindan lactic acid technology (300829.SZ) released its performance for the first three quarters, with a net income of 0.102 billion yuan, a year-on-year increase of 7.1%.
Henan Jindan Lactic Acid Technology (300829.SZ) released the third quarter report of 2024, with revenue for the first three quarters reaching...
Henan Jindan Lactic Acid Technology (300829.SZ): Currently, the main products are lactic acid, sodium lactate, and calcium lactate.
Gelonghui October 10th | Henan Jindan Lactic Acid Technology (300829.SZ) stated on the investor interaction platform that the company's main products currently are lactic acid, sodium lactate, and calcium lactate. Lactic acid, as an organic acid naturally present in the human body, has good biocompatibility, can be fully absorbed by the body, and lactic acid series products have functions such as preservation, freshness, and improving food flavor, and are widely used as additives in the food, fodder, pharmaceutical, and other fields; Additionally, lactic acid can also synergistically increase efficiency with other additives to replace sodium dehydroacetate. Sodium dehydroacetate, as a food additive, has been widely used in the past in baking and baked goods.
September 11th A-shares Lightning Rod | Henan Jindan Lactic Acid Technology: Guangzhou Chengxin, a shareholder, plans to reduce its shareholding by no more than 2.99%; ST Xulan: Stock trading may be subject to delisting risk warning.
Henan Jindan Lactic Acid Technology's shareholder, Guangzhou Chengxin, plans to reduce its shareholding by no more than 2.99%; Anfu Ce Link Limited's special shareholder, Dasheng Investment and Hesheng Investment, plan to collectively reduce their shareholding by no more than 1.65 million shares; Weide Information has terminated the planning of major asset restructuring; Improve Medical Instruments' subsidiary's business does not include human stem cell, gene diagnosis and treatment technology development and application; There is a possibility for special treat Xulan stocks to be subject to delisting risk warning.
Express News | Henan Jindan Lactic Acid Technology: Shareholder Guangzhou Chengxin plans to reduce its shareholding by no more than 2.99%.
No Data
No Data